Business description
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability. Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese Encephalitis (IXIARO®) and the second (DUKORAL®) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC (Enterotoxigenic Escherichia coli). The Company has proprietary vaccines in development including candidates against Pseudomonas aeruginosa, Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant). Valneva is headquartered in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Scotland and Sweden with approximately 400 employees.
Management board & Supervisory board
CEO |
Thomas Lingelbach |
Management board |
Franck Grimaud, Frédéric Jacotot, Juan Carlos Jaramillo |
Supervisory board |
Frédéric Grimaud, Anne-Marie Graffin, James Sulat, Johanna Willemina Pattenier, Sharon Tetlow |
Company data
Name: |
Valneva SE |
Address: |
World Trade Center Lyon, 10-12 Boulevard Vivier Merle,F-69003 Lyon |
Phone: |
+33-478-7661-01 |
Fax: |
- |
E-mail: |
info@valneva.com
|
Internet: |
www.valneva.com/ |
Industry: |
Biotechnology |
Sector: |
Biotechnology |
Sub sector: |
Biotechnology |
End of financial year: |
12-31 |
Free Float: |
77.40% |
IPO date: |
2013-05-28 |
Investor relations
Name: |
Laetitia Bachelot-Fontaine |
IR phone: |
+33-22807-3710 |
IR Fax: |
- |
IR e-mail: |
investors@valneva.com
|